May 22 |
BioVie’s Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson’s Disease Patients
|
Apr 29 |
BioVie awarded up to $13.1M in funding from U.S. DOD for long COVID treatment
|
Apr 29 |
BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID
|
Apr 25 |
BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer’s Disease and Biomarker Endpoints
|
Apr 18 |
BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation
|
Apr 12 |
Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
|
Mar 12 |
Bears are Losing Control Over BioVie Inc. (BIVI), Here's Why It's a 'Buy' Now
|
Mar 11 |
BioVie Announces Pipeline Update and Near-Term Clinical Priorities
|
Mar 6 |
BioVie Inc. Announces Closing of Public Offering
|
Mar 4 |
BioVie stock plunges 43% following public offering pricing
|